133 related articles for article (PubMed ID: 38309148)
21. Canavan disease: a monogenic trait with complex genomic interaction.
Surendran S; Michals-Matalon K; Quast MJ; Tyring SK; Wei J; Ezell EL; Matalon R
Mol Genet Metab; 2003; 80(1-2):74-80. PubMed ID: 14567959
[TBL] [Abstract][Full Text] [Related]
22. Loss of central auditory processing in a mouse model of Canavan disease.
von Jonquieres G; Froud KE; Klugmann CB; Wong AC; Housley GD; Klugmann M
PLoS One; 2014; 9(5):e97374. PubMed ID: 24826990
[TBL] [Abstract][Full Text] [Related]
23. Novel splice site mutation of aspartoacylase gene in a Turkish patient with Canavan disease.
Rady PL; Penzien JM; Vargas T; Tyring SK; Matalon R
Eur J Paediatr Neurol; 2000; 4(1):27-30. PubMed ID: 10701101
[TBL] [Abstract][Full Text] [Related]
24. A missense mutation (p.G274R) in gene ASPA causes Canavan disease in a Pakistani family.
Hussain R; Daud S; Kakar N; Ahmad A; Baloch AH; Tareen AM; Kakar MA; Ahmad J
Mol Biol Rep; 2012 May; 39(5):6197-201. PubMed ID: 22219087
[TBL] [Abstract][Full Text] [Related]
25. Two patients with Canavan disease and structural modeling of a novel mutation.
Zaki OK; Krishnamoorthy N; El Abd HS; Harche SA; Mattar RA; Al Disi RS; Nofal MY; El Bekay R; Ahmed KA; George Priya Doss C; Zayed H
Metab Brain Dis; 2017 Feb; 32(1):171-177. PubMed ID: 27531131
[TBL] [Abstract][Full Text] [Related]
26. Cloning of the human aspartoacylase cDNA and a common missense mutation in Canavan disease.
Kaul R; Gao GP; Balamurugan K; Matalon R
Nat Genet; 1993 Oct; 5(2):118-23. PubMed ID: 8252036
[TBL] [Abstract][Full Text] [Related]
27. Novel mutation in an Egyptian patient with infantile Canavan disease.
Zaki OK; El Abd HS; Mohamed SA; Zayed H
Metab Brain Dis; 2016 Jun; 31(3):573-7. PubMed ID: 26613958
[TBL] [Abstract][Full Text] [Related]
28. Adeno-associated virus-mediated aspartoacylase gene transfer to the brain of knockout mouse for canavan disease.
Matalon R; Surendran S; Rady PL; Quast MJ; Campbell GA; Matalon KM; Tyring SK; Wei J; Peden CS; Ezell EL; Muzyczka N; Mandel RJ
Mol Ther; 2003 May; 7(5 Pt 1):580-7. PubMed ID: 12718900
[TBL] [Abstract][Full Text] [Related]
29. Restoration of aspartoacylase activity in CNS neurons does not ameliorate motor deficits and demyelination in a model of Canavan disease.
Klugmann M; Leichtlein CB; Symes CW; Serikawa T; Young D; During MJ
Mol Ther; 2005 May; 11(5):745-53. PubMed ID: 15851013
[TBL] [Abstract][Full Text] [Related]
30. Brain Nat8l Knockdown Suppresses Spongiform Leukodystrophy in an Aspartoacylase-Deficient Canavan Disease Mouse Model.
Bannerman P; Guo F; Chechneva O; Burns T; Zhu X; Wang Y; Kim B; Singhal NK; McDonough JA; Pleasure D
Mol Ther; 2018 Mar; 26(3):793-800. PubMed ID: 29456021
[TBL] [Abstract][Full Text] [Related]
31. Mutational analysis of aspartoacylase: implications for Canavan disease.
Hershfield JR; Pattabiraman N; Madhavarao CN; Namboodiri MA
Brain Res; 2007 May; 1148():1-14. PubMed ID: 17391648
[TBL] [Abstract][Full Text] [Related]
32. A case of Canavan disease with microcephaly.
Gowda VK; Bhat MD; Srinivasan VM; Prasad C; Benakappa A; Faruq M
Brain Dev; 2016 Sep; 38(8):759-62. PubMed ID: 26992473
[TBL] [Abstract][Full Text] [Related]
33. Atypical MRI findings in Canavan disease: a patient with a mild course.
Yalcinkaya C; Benbir G; Salomons GS; Karaarslan E; Rolland MO; Jakobs C; van der Knaap MS
Neuropediatrics; 2005 Oct; 36(5):336-9. PubMed ID: 16217711
[TBL] [Abstract][Full Text] [Related]
34. Canavan disease: genomic organization and localization of human ASPA to 17p13-ter and conservation of the ASPA gene during evolution.
Kaul R; Balamurugan K; Gao GP; Matalon R
Genomics; 1994 May; 21(2):364-70. PubMed ID: 8088831
[TBL] [Abstract][Full Text] [Related]
35. N-acetylaspartate supports the energetic demands of developmental myelination via oligodendroglial aspartoacylase.
Francis JS; Wojtas I; Markov V; Gray SJ; McCown TJ; Samulski RJ; Bilaniuk LT; Wang DJ; De Vivo DC; Janson CG; Leone P
Neurobiol Dis; 2016 Dec; 96():323-334. PubMed ID: 27717881
[TBL] [Abstract][Full Text] [Related]
36. Canavan disease: mutations among Jewish and non-Jewish patients.
Kaul R; Gao GP; Aloya M; Balamurugan K; Petrosky A; Michals K; Matalon R
Am J Hum Genet; 1994 Jul; 55(1):34-41. PubMed ID: 8023850
[TBL] [Abstract][Full Text] [Related]
37. Clinically Distinct Phenotypes of Canavan Disease Correlate with Residual Aspartoacylase Enzyme Activity.
Mendes MI; Smith DE; Pop A; Lennertz P; Fernandez Ojeda MR; Kanhai WA; van Dooren SJ; Anikster Y; Barić I; Boelen C; Campistol J; de Boer L; Kariminejad A; Kayserili H; Roubertie A; Verbruggen KT; Vianey-Saban C; Williams M; Salomons GS
Hum Mutat; 2017 May; 38(5):524-531. PubMed ID: 28101991
[TBL] [Abstract][Full Text] [Related]
38. Feline Spongy Encephalopathy With a Mutation in the
Takaichi Y; Chambers JK; Shiroma-Kohyama M; Haritani M; Une Y; Yamato O; Nakayama H; Uchida K
Vet Pathol; 2021 Jul; 58(4):705-712. PubMed ID: 33779415
[TBL] [Abstract][Full Text] [Related]
39. Molecular characterisation and prenatal diagnosis of Asparto-acylase deficiency (Canavan disease)--report of two novel and two known mutations from the Indian subcontinent.
Bijarnia S; Kohli S; Puri RD; Jacob RJ; Saxena R; Jalan A; Sistermans EA; Mahmood S; Verma IC
Indian J Pediatr; 2013 Jan; 80(1):26-31. PubMed ID: 22878930
[TBL] [Abstract][Full Text] [Related]
40. Clinical protocol. Gene therapy of Canavan disease: AAV-2 vector for neurosurgical delivery of aspartoacylase gene (ASPA) to the human brain.
Janson C; McPhee S; Bilaniuk L; Haselgrove J; Testaiuti M; Freese A; Wang DJ; Shera D; Hurh P; Rupin J; Saslow E; Goldfarb O; Goldberg M; Larijani G; Sharrar W; Liouterman L; Camp A; Kolodny E; Samulski J; Leone P
Hum Gene Ther; 2002 Jul; 13(11):1391-412. PubMed ID: 12162821
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
